Gastroenterology :炎性肠病的手术风险随着时间推移已逐渐降低

2013-12-02 吴军 编译 医学论坛网

炎性肠病(IBDs)是慢性疾病,通常需要手术治疗;但是随着时间的推移,手术风险情况并未被较好的描述。来自加拿大Calgary大学的Alexandra D. Frolkis等进行了一项系统性综述及荟萃分析,来明确炎症性肠病患者手术累计风险及评价手术风险如何随时间推移而改变。研究结果显示在过去的60年内,炎症性肠病患者的手术风险已逐渐减少。该文发表于近期《胃肠病学》杂志。(

炎性肠病(IBDs)是慢性疾病,通常需要手术治疗;但是随着时间的推移,手术风险情况并未被较好的描述。来自加拿大Calgary大学的Alexandra D. Frolkis等进行了一项系统性综述及荟萃分析,来明确炎症性肠病患者手术累计风险及评价手术风险如何随时间推移而改变。研究结果显示在过去的60年内,炎症性肠病患者的手术风险已逐渐减少。该文发表于近期《胃肠病学》杂志。(Gastroenterology,2013,145:996-1006)【原文下载

研究者搜索了MEDLINE、EMBASE、Pubmed和会议摘要(2009-2012)中与IBD及肠道手术有关文献;2名评价者筛查了8338篇摘要,最终纳入了30篇基于人群的研究,包括文章发表(26篇)和摘要(4篇),报道了在诊断CD或UC后1、5、10年的手术风险。通过meta回归随机效应模型来分析随时间推移手术风险趋势。

基于人群研究,在诊断CD后1年、5年、10年时手术风险分别为16.3% (95%CI,11.4%-23.2%), 33.3% (95%CI,26.3%-42.1%),46.6%(95%CI,37.7%-57.7%);在诊断UC后1年、5年、10年时手术风险分别为4.9% (95%CI,3.8%-6.3%), 11.6% (95%CI, 9.3%-14.4%), 15.6% (95%CI,12.5%-19.6%);在诊断CD后1、5、10年时和诊断UC后1、10年时的手术风险在过去的60年内显著下降。

原文出处

Frolkis AD, Dykeman J, Negrón ME, Debruyn J, Jette N, Fiest KM, Frolkis T, Barkema HW, Rioux KP, Panaccione R, Ghosh S, Wiebe S, Kaplan GG.Risk of Surgery for Inflammatory Bowel Diseases Has Decreased Over Time: A Systematic Review and Meta-analysis of Population-Based Studies.Gastroenterology. 2013 Nov;1【原文下载

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2063874, encodeId=47e820638e4ef, content=<a href='/topic/show?id=94ffe853a7' target=_blank style='color:#2F92EE;'>#Gastroenterol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7853, encryptionId=94ffe853a7, topicName=Gastroenterol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Wed Dec 11 01:48:00 CST 2013, time=2013-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2071518, encodeId=376c20e15181a, content=<a href='/topic/show?id=9d4ee84647' target=_blank style='color:#2F92EE;'>#GAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7846, encryptionId=9d4ee84647, topicName=GAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Sat Sep 13 13:48:00 CST 2014, time=2014-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710689, encodeId=12981e1068974, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Fri Mar 21 21:48:00 CST 2014, time=2014-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1504177, encodeId=22bd15041e760, content=<a href='/topic/show?id=7730e85412' target=_blank style='color:#2F92EE;'>#Gastroenterology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7854, encryptionId=7730e85412, topicName=Gastroenterology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Wed Dec 04 01:48:00 CST 2013, time=2013-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548437, encodeId=3825154843e9a, content=<a href='/topic/show?id=860c545197f' target=_blank style='color:#2F92EE;'>#手术风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54519, encryptionId=860c545197f, topicName=手术风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c8f14082259, createdName=huagfeg, createdTime=Wed Dec 04 01:48:00 CST 2013, time=2013-12-04, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2063874, encodeId=47e820638e4ef, content=<a href='/topic/show?id=94ffe853a7' target=_blank style='color:#2F92EE;'>#Gastroenterol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7853, encryptionId=94ffe853a7, topicName=Gastroenterol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Wed Dec 11 01:48:00 CST 2013, time=2013-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2071518, encodeId=376c20e15181a, content=<a href='/topic/show?id=9d4ee84647' target=_blank style='color:#2F92EE;'>#GAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7846, encryptionId=9d4ee84647, topicName=GAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Sat Sep 13 13:48:00 CST 2014, time=2014-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710689, encodeId=12981e1068974, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Fri Mar 21 21:48:00 CST 2014, time=2014-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1504177, encodeId=22bd15041e760, content=<a href='/topic/show?id=7730e85412' target=_blank style='color:#2F92EE;'>#Gastroenterology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7854, encryptionId=7730e85412, topicName=Gastroenterology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Wed Dec 04 01:48:00 CST 2013, time=2013-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548437, encodeId=3825154843e9a, content=<a href='/topic/show?id=860c545197f' target=_blank style='color:#2F92EE;'>#手术风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54519, encryptionId=860c545197f, topicName=手术风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c8f14082259, createdName=huagfeg, createdTime=Wed Dec 04 01:48:00 CST 2013, time=2013-12-04, status=1, ipAttribution=)]
    2014-09-13 许安
  3. [GetPortalCommentsPageByObjectIdResponse(id=2063874, encodeId=47e820638e4ef, content=<a href='/topic/show?id=94ffe853a7' target=_blank style='color:#2F92EE;'>#Gastroenterol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7853, encryptionId=94ffe853a7, topicName=Gastroenterol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Wed Dec 11 01:48:00 CST 2013, time=2013-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2071518, encodeId=376c20e15181a, content=<a href='/topic/show?id=9d4ee84647' target=_blank style='color:#2F92EE;'>#GAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7846, encryptionId=9d4ee84647, topicName=GAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Sat Sep 13 13:48:00 CST 2014, time=2014-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710689, encodeId=12981e1068974, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Fri Mar 21 21:48:00 CST 2014, time=2014-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1504177, encodeId=22bd15041e760, content=<a href='/topic/show?id=7730e85412' target=_blank style='color:#2F92EE;'>#Gastroenterology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7854, encryptionId=7730e85412, topicName=Gastroenterology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Wed Dec 04 01:48:00 CST 2013, time=2013-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548437, encodeId=3825154843e9a, content=<a href='/topic/show?id=860c545197f' target=_blank style='color:#2F92EE;'>#手术风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54519, encryptionId=860c545197f, topicName=手术风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c8f14082259, createdName=huagfeg, createdTime=Wed Dec 04 01:48:00 CST 2013, time=2013-12-04, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2063874, encodeId=47e820638e4ef, content=<a href='/topic/show?id=94ffe853a7' target=_blank style='color:#2F92EE;'>#Gastroenterol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7853, encryptionId=94ffe853a7, topicName=Gastroenterol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Wed Dec 11 01:48:00 CST 2013, time=2013-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2071518, encodeId=376c20e15181a, content=<a href='/topic/show?id=9d4ee84647' target=_blank style='color:#2F92EE;'>#GAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7846, encryptionId=9d4ee84647, topicName=GAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Sat Sep 13 13:48:00 CST 2014, time=2014-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710689, encodeId=12981e1068974, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Fri Mar 21 21:48:00 CST 2014, time=2014-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1504177, encodeId=22bd15041e760, content=<a href='/topic/show?id=7730e85412' target=_blank style='color:#2F92EE;'>#Gastroenterology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7854, encryptionId=7730e85412, topicName=Gastroenterology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Wed Dec 04 01:48:00 CST 2013, time=2013-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548437, encodeId=3825154843e9a, content=<a href='/topic/show?id=860c545197f' target=_blank style='color:#2F92EE;'>#手术风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54519, encryptionId=860c545197f, topicName=手术风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c8f14082259, createdName=huagfeg, createdTime=Wed Dec 04 01:48:00 CST 2013, time=2013-12-04, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2063874, encodeId=47e820638e4ef, content=<a href='/topic/show?id=94ffe853a7' target=_blank style='color:#2F92EE;'>#Gastroenterol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7853, encryptionId=94ffe853a7, topicName=Gastroenterol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Wed Dec 11 01:48:00 CST 2013, time=2013-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2071518, encodeId=376c20e15181a, content=<a href='/topic/show?id=9d4ee84647' target=_blank style='color:#2F92EE;'>#GAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7846, encryptionId=9d4ee84647, topicName=GAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Sat Sep 13 13:48:00 CST 2014, time=2014-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710689, encodeId=12981e1068974, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Fri Mar 21 21:48:00 CST 2014, time=2014-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1504177, encodeId=22bd15041e760, content=<a href='/topic/show?id=7730e85412' target=_blank style='color:#2F92EE;'>#Gastroenterology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7854, encryptionId=7730e85412, topicName=Gastroenterology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Wed Dec 04 01:48:00 CST 2013, time=2013-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548437, encodeId=3825154843e9a, content=<a href='/topic/show?id=860c545197f' target=_blank style='color:#2F92EE;'>#手术风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54519, encryptionId=860c545197f, topicName=手术风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c8f14082259, createdName=huagfeg, createdTime=Wed Dec 04 01:48:00 CST 2013, time=2013-12-04, status=1, ipAttribution=)]

相关资讯

Inflamm Bowel Dis:武汉炎性肠病(IBD)的流行病学调查

西方国家炎性肠病(IBD)的发病率较高,在中国的发病率比较低,但现在随着时间推移IBD在中的发病率也逐渐升高。不过目前中国IBD的发病率还 不明确。为此来自武汉大学中南医院的JieZhao等人进行一项研究,该研究结果发表在8月份的Inflammatory Bowel Diseases上,研究主要是通过以普通人群为基础的方法调查武汉市的IBD发病率及该人群中IBD的临床表型。 这是一项前

AP&T:炎性肠病成年患者BMI明显下降

关于炎性肠病(IBD)患者的身体成分组成资料很少。脂肪和肌肉成分的改变可能影响骨骼健康、肌肉性能、生活质量及整体发病率。来自美国的R. V. Bryant、M. J. Trott近日发表论文,该研究系统回顾与IBD成年患者身体成分组成相关的文献,并探讨其中潜在的促成因素及相互关系。研究显示,目前的资料,尽管多种多样,都表明许多IBD患者其脂肪组织和肌肉组织的

DCR:术前应用英夫利昔单抗不增加炎性肠病患者腹腔镜下切除后死亡率

  近日,《结肠与直肠疾病》(Diseases of the Colon & Rectum)杂志载文评价了英夫利昔单抗对在接受择期腹腔下切除术的炎性肠病(IBD)患者围术期转归的影响。文章发表于2013年第56卷第4期。   该文作者Mukta Krane对经过伦理委员会批准后前瞻性收集的数据库进行了回顾性分析。   该团队对

GUT:炎性肠病与生活方式相关

  近日,一项关于多个国家和地区的研究指出,炎性肠病(IBD)随时间及地理而变化的流行病学提示环境因素在疾病表达的改变中发挥重要作用。该疾病在发展中国家的出现提示流行病学进展与西方化的生活方式以及工业化相关。该文发表在2013年第63卷第4期《消化道》(GUT)杂志上。   来自香港的Siew Ng医师指出,已发现的最强的环境相关因素为吸烟和阑尾切除,不过两种因素均不足以单独解释

IBD:英夫利昔监测可有效预测炎性肠病患者粘膜愈合情况

目前关于利用英夫利昔治疗来预测炎症性肠病患者粘膜愈合情况的确凿数据仍然匮乏,针对这种情况,来自法国圣艾蒂安免疫学与免疫监测实验室的Paul Stephane博士等人进行了一项研究,研究结果发表于2013年11月的《炎症性肠病》(Inflammatory Bowel Diseases)上。研究发现:英夫利昔的药物监测可有效地预测炎症性肠病患者的粘膜愈合情况。【原文下载】 研究对2010年6月-20

Science:肠道中硝酸盐能促进大肠杆菌生长,加重炎性肠病

    一直以来科学家们都有一个困扰:那些有害的细菌,如大肠杆菌,为什么会在炎症性肠病患者的肠道内大肆生长,并引起严重的腹泻呢。如今,UC Davis 的研究员们找到了答案,而这意味着我们在更好地治疗炎症性肠病的道路上迈出了第一步。     研究员们发现了一种生物学机制,在这种机制下有害细菌在炎症性肠病患者体内生长,逐步排挤有益细菌,并